Concerns dampen Chugai's hopes for Epogin in chemotherapy-induced anaemia
This article was originally published in Scrip
Executive Summary
Roche's subsidiary Chugai has been told by an official panel in Japan that it is "not appropriate" for its recombinant erythropoietin product Epogin (epoetin beta) to be approved for the additional indication of chemotherapy-induced anaemia (CIA).